Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Brexucabtagene Autoleucel Provides New Option for Patients With R/R MCL
Brexucabtagene autoleucel induced durable response in patients with relapsed/refractory mantle cell lymphoma, according to findings from the phase 2 ZUMA-2 trial, leading to an FDA approval for use in this patient population on July 24, 2020.
Use of daratumumab for transplant-ineligible myeloma
During a Targeted Oncology Case-Based Peer Perspective event, Rafael Fonseca, MD, discussed the case of a 72-year-old patient with multiple myeloma.
Scientists create ON-OFF switches to control CAR T cell activity
Scientists at Dana-Farber Cancer Institute and Mass General Cancer Center have created molecular ON-OFF switches to regulate the activity of CAR T cells, a potent form of cell-based immunotherapy that has had dramatic success in treating some advanced cancers, but which pose a significant risk of toxic side effects.
Patient Resource: Latest News on CAR T-Cell Therapy for Multiple Myeloma
How can CAR T-cell therapy be used to treat multiple myeloma, and what is the latest in CAR T-cell research? Is it getting closer to being an approved treatment option? What are we learning from clinical trials? And finally, what should patients know?
Interim results from ZUMA-12: Axi-cel as frontline treatment for high-risk LBCL
Patients with high-risk large B-cell lymphoma (LBCL) are mainly treated with rituximab-based chemoimmunotherapies that do not provide sufficient efficacy, as approximately 50% of these patients will not achieve long-term disease remission.
T-cell engaging antibodies for hematological diseases from approved therapies to...
Are bispecific antibodies less effective (and less toxic) than CAR-T cells? This educational video from the EHA25 congress shows us that the race between CAR-T therapy and bispecific Abs for hematological diseases is still ongoing!
Liso-Cel BLA for Relapsed/Refractory LBCL Remains Under FDA Review
The biologics license application for the CAR T-cell product lisocabtagene maraleucel in adult patients with relapsed/refractory large B-cell lymphoma following at least 2 previous therapies continues to be under regulatory review by the FDA, and a decision on the application has not yet been reached.
Treating Double-Hit Lymphoma With CAR T-Cell Therapy and Other Drugs
During a Targeted Oncology Case-Based Peer Perspectives event, Haifaa Abdulhaq, MD, director, Hematology, and associate clinical professor of Medicine at UCSF Fresno discussed the case of a 63-year-old patient with lymphoma with concurrent MYC and BCL2 rearrangements.
Comparing efficacy outcomes of ide-cel versus conventional care in R/R myeloma
Nina Shah, MD, University of California-San Francisco, San Francisco, CA, discusses an analysis that compared efficacy outcomes seen in the MAMMOTH study, a retrospective observational study of conventional care regimens, and the KarMMA trial (NCT03361748) of the BCMA-targeted CAR-T cell therapy idecabtagene vicleucel (ide-cel), both in triple-class refractory multiple myeloma patients.
DARAZADEX: a Phase II trial of daratumumab plus azacitidine and dexamethasone in...
Nina Shah, MD, University of California-San Francisco, San Francisco, CA, shares the details of an ongoing Phase II trial (NCT04407442) of daratumumab, an anti-CD38 monoclonal antibody, in combination with azacitidine and dexamethasone in relapsed/refractory (R/R) multiple myeloma patients.